CAN-2409 Shows 30% Improvement in Disease-Free Survival Across Radiation Types in Phase 3 Prostate Cancer Trial
Landmark Trial Signals First Major Advancement in Localized Prostate Cancer in Over Two Decades
Candel Therapeutics announced at the 2025 ASTRO annual meeting that its lead investigational immunotherapy, CAN-2409, produced a 30% improvement in disease-free survival (DFS) for patients with intermediate-to-high-risk localized prostate cancer when combined with standard radiation. Significantly, this benefit held true regardless of whether patients received conventional or moderate hypofractionated radiotherapy.
Key Phase 3 Outcomes: Durable Benefit and Broad Compatibility
In the double-blind, placebo-controlled, multicenter phase 3 trial (NCT01436968), 745 patients were randomized 2:1 to either CAN-2409 plus valacyclovir with standard radiation, or standard therapy alone. The addition of CAN-2409 achieved a hazard ratio of 0.7 for DFS (p=0.0155) and a 38% improvement in prostate cancer-specific DFS (HR 0.62, p=0.0046). At two years, pathological complete response rates reached 80.4% for the CAN-2409 arm versus 63.6% for controls (p=0.0015).
Results also showed CAN-2409 was effective across both major external beam radiation regimens:
| Radiation Modality | Prostate Cancer-Specific DFS (HR) | 95% Confidence Interval | p-value |
|---|---|---|---|
| Moderate Hypofractionated EBRT (60 Gy/3 Gy fractions) | 0.52 | 0.30 – 0.93 | 0.02 |
| Conventional EBRT (~78 Gy/2 Gy fractions) | 0.76 | 0.53 – 1.07 | 0.11 |
Safety Profile Remains Favorable and Consistent
The safety profile of CAN-2409 was reassuring, with rates of Grade 3 treatment-related adverse events nearly identical between treatment and control arms. For both moderate hypofractionated and conventional radiation, rates of these adverse events ranged from 1.1% to 1.9% in all groups. This supports CAN-2409 as a viable addition to standard radiation therapies without introducing additional significant risks.
Regulatory Pathway and Future Outlook
With a Biologics License Application (BLA) planned for late 2026, these results put Candel’s CAN-2409 in a leading position for potentially changing the treatment paradigm in localized prostate cancer, an area with limited progress over the past 20 years. The therapy also holds Fast Track and Regenerative Medicine Advanced Therapy designations for various solid tumors, with over 1,000 patients treated in clinical studies so far.
Takeaway: Broad Efficacy, Consistent Benefit, and Approaching Regulatory Milestone
CAN-2409’s consistent efficacy, regardless of radiation modality, positions it as a compelling future option for localized, non-metastatic prostate cancer. Investors and clinicians alike should monitor developments closely as the company moves towards BLA submission in late 2026—a move that could mark the most significant advancement for this cancer population in a generation.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI